Sanofi

CompanyFranceFounded 2004

RORWikidata

Sanofi develops 85 assets, the furthest approved (alirocumab in hypercholesterolemia). Mostly small molecule and vaccine acting on INSR, GLP1R and DPP4; based in France, founded in 2004.

85
Assets
Furthest stage
Approved
1,033
Trials
254
Signals

Pipeline

85
  • alirocumab

    Inhibits PCSK9, increasing LDL receptor recycling and lowering circulating LDL cholesterol.

    Approved, Antibody, PCSK9, hypercholesterolemia, heterozygous familial hypercholesterolemia

  • Alogliptin

    Inhibits DPP-4, increasing incretin activity to enhance glucose-dependent insulin secretion and reduce glucagon secretion.

    Approved, Small molecule, DPP4, type 2 diabetes, diabetes mellitus (Phase 3)

  • Amaryl

    Approved, not sold in the US, Small molecule, ABCC8, KCNJ11, type 2 diabetes (Phase 3), diabetes mellitus (Phase 3)

82 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

10

In the full profile

  • Evidence behind the mechanisms11
  • Trials1,696
  • Deals3
  • Signals20
  • Integrity notices3
  • Similar companies6

Papers

Intelligence